Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June 2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's disease (AD) approved by the US Food and Drug Administration (FDA), under the accelerated approval pathway. The decision was based on the ability of aducanumab to remove Aβ plaques, without any evidence that the Aβ clearance is correlated with less cognitive or functional decline. This decision has generated a considerable debate in the scientific community, especially because the results from the two Phase 3 trials, EMERGE and ENGAGE, were divergent and, even after the post hoc analysis, the data were insufficient to prove aducanumab efficacy. Moreover, some researchers think that this approval will be an obstacle to the progress and also demonstrated concerns about aducanumab cost and its safety profile. The European Medicines Agency's rejection of aducanumab in December 2021 just brought more controversy over FDA's decision. Now, Biogen is designing the FDA's required confirmatory study, named ENVISION, which should be complete in 2026. Despite the controversy, the aducanumab showed to affect downstream tau pathology, which could open doors for a combination therapy approach for AD (anti-tau and anti-amyloid drug). This review summarizes the clinical development of aducanumab until regulatory agencies' decisions, the available trials data and the controversy over aducanumab approval for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the EMERGE experiment, when participants with AD were at risk for cognitive deterioration, there was a decrease in the amount of amyloid-beta plaques.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [132]
In the citing paper
“Aducanumab demonstrated inconsistent outcomes in its two main clinical trials, the Phase III EMERGE and ENGAGE research investigations.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [132]
In the citing paper
“In spite of this, the FDA granted expedited approval on the grounds of the EMERGE trial’s documented decrease in amyloid levels [132,185,186,187].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“According to the amyloid cascade hypothesis, the extracellular accumulation of Aβ aggregates is the leading cause of synapses dysfunction, neuroinflammation, neuronal loss and is also the trigger of tau pathology.(7) Thus, researchers believe that Aβ clearance by aducanumab is a rational mechanism to slow cognitive de…”
BackgroundThe neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 1×
“These drugs temporary attenuate symptoms but do not target AD’s two main recognized pathological features: extracellular deposits of amyloid β (Aβ) in plaques and intracellular neurofibrillary tangles (comprised of abnormal tau protein).(3,4) On June 7, 2021, aducanumab (AduhelmTM, Biogen) became the first disease-mod…”
BackgroundAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · cited 1×
“Aducanumab: Selective Anti-Aβ Antibody Over the last 25 years, several drugs targeting Aβ have failed to show clinical efficacy in trials, including five anti-Aβ antibodies: bapineuzumab, solanezumab, crenezumab, ponezumab, and gantenerumab.(25,26) Thus, supporters of the amyloid hypothesis placed high hopes on aducan…”
BackgroundThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 4×
“Aducanumab is a monoclonal antibody selective for aggregated forms of Aβ, with demonstrated efficacy in the clearance of brain Aβ plaques.(6) According to the amyloid cascade hypothesis, the extracellular accumulation of Aβ aggregates is the leading cause of synapses dysfunction, neuroinflammation, neuronal loss and i…”
BackgroundMethodInfluentialLane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616 · cited 1×
“These drugs temporary attenuate symptoms but do not target AD’s two main recognized pathological features: extracellular deposits of amyloid β (Aβ) in plaques and intracellular neurofibrillary tangles (comprised of abnormal tau protein).(3,4) On June 7, 2021, aducanumab (AduhelmTM, Biogen) became the first disease-mod…”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947 · cited 2×
“ARIAs are abnormal findings detected in brain magnetic resonance imaging (MRI) and can present as brain edema or sulcal effusions (ARIA-E) and as intracerebral hemorrhage often accompanied by superficial hemosiderin deposits (ARIA-H).(52) Although the mechanism leading to ARIA remains not fully understood, studies sug…”
BackgroundThe Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“Although the mechanism leading to ARIA remains not fully understood, studies suggest that Aβ clearance causes damage to vessel walls which increases the cerebrovascular permeability and the risk of hemorrhage.(52,53) ARIA has been associated with anti-Aβ antibodies therapies and was reported in the phase 1b trial of a…”
BackgroundSalloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619 · cited 4×
“Salloway et al published the combined safety data from the ENGAGE and EMERGE trials in December 2021.(21) However, we presented the ARIA incidence for each study independently in Table 3.”
BackgroundInfluentialLa Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5732 · Cited by 612 · cited 1×
“Moreover, recent studies showed that tau accumulation correlates better with cognitive impairment than Aβ.(61,62) Thirdly, the close collaboration between the FDA and the sponsor could have impacted the objectivity of the FDA’s decision.”
BackgroundAlzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547 · cited 1×
“Aducanumab: Selective Anti-Aβ Antibody Over the last 25 years, several drugs targeting Aβ have failed to show clinical efficacy in trials, including five anti-Aβ antibodies: bapineuzumab, solanezumab, crenezumab, ponezumab, and gantenerumab.(25,26) Thus, supporters of the amyloid hypothesis placed high hopes on aducan…”
BackgroundSelf-citationKnopman, D. S., Jones, D. T., & Greicius, M. D. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12213 · Cited by 524
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 365 · cited 1×
“Hence, the high selectivity of aducanumab for Aβ aggregates, including soluble oligomers and insoluble fibrils, constitutes a major advantage over previous anti-Aβ antibodies.(30) Studies demonstrated that aducanumab’s binding promotes the clearance of Aβ aggregates through the activation of microglial phagocytosis.”
BackgroundA trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359
Aducanumab: Appropriate Use Recommendations
Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.41 · Cited by 316 · cited 2×
“ApoE genotype screening is optional, despite the high risk of ARIA in ApoE4 carriers.(69) The panel also requires aducanumab titration to the target dose of 10 mg/kg over 6 months, and this dose is continued for the future (Figure 2).”
BackgroundChen, X.-Q., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 289
Avgerinos, K. I., Ferrucci, L., & Kapogiannis, D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101339 · Cited by 240
Alexander, G. C., Emerson, S., & Kesselheim, A. S. (2021) · JAMA · doi:10.1001/jama.2021.3854 · Cited by 240 · cited 1×
“Thirdly, the close collaboration between the FDA and the sponsor could have impacted the objectivity of the FDA’s decision.(63,64) Furthermore, the AD ́s advocacy groups exerted much pressure on the FDA, defending that a marginal benefit of aducanumab would be significant to patients and caregivers.”
BackgroundAducanumab produced a clinically meaningful benefit in association with amyloid lowering
Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00838-z · Cited by 224
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies
Linse, S., Scheidt, T., Bernfur, K., Vendruscolo, M., Dobson, C. M., Cohen, S. I. A., Sileikis, E., Lundqvist, M., Qian, F., O’Malley, T., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0505-6 · Cited by 201 · cited 1×
“Besides the clearance, aducanumab is the only antibody that disrupts the Aβ aggregation process by inhibiting the secondary nucleation (formation of oligomers on the fibril surface) due to its affinity and binding stoichiometry to Aβ aggregates.(19,31) These reasons made aducanumab the most promising drug for AD of th…”
BackgroundAducanumab: evidence from clinical trial data and controversies
Tampi, R. R., Forester, B. P., & Agronin, M. (2021) · Drugs in Context · doi:10.7573/dic.2021-7-3 · Cited by 190 · cited 14×
“In Europe, aducanumab was under review at the EMA since October 2020 (Figure 1).14,42 On December 17, 2021, the EMA’s Committee for Medicinal Products for Human Use recommended the rejection of the marketing application for Aduhelm™.22,43,44 According to the performed studies, EMA experts considered that this drug did…”
BackgroundResultInfluentialFerrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., & Sevigny, J. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.002 · Cited by 189 · cited 1×
“The study showed a reasonable safety profile and linear PK at doses ≤ 30mg/ kg.(34) In 2012, a phase 1b randomized trial, denominated PRIME (study 103, NCT01677572), started with mild cognitive impairment (MCI) and mild AD patients who had brain Aβ plaques confirmed by positron emission tomography (PET) imaging.”
BackgroundRevisiting FDA Approval of Aducanumab
Alexander, G. C., Knopman, D. S., Emerson, S. S., Ovbiagele, B., Kryscio, R. J., Perlmutter, J. S., & Kesselheim, A. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2110468 · Cited by 162 · cited 1×
“Secondly, there is no evidence that Aβ reduction correlates with clinical benefits, so the majority of experts consider that Aβ plaques are not a valid surrogate endpoint.(10,60) Moreover, recent studies showed that tau accumulation correlates better with cognitive impairment than Aβ.”
BackgroundAducanumab for Alzheimer’s disease?
Walsh, S., Merrick, R., Milne, R., & Brayne, C. (2021) · BMJ · doi:10.1136/bmj.n1682 · Cited by 159 · cited 3×
“Finally, there was controversy over the FDA prescribing label for aducanumab because it was initially approved for anyone with AD, despite the trials only enrolled MCI and mild AD patients.(13) Only after a month, the FDA narrowed the indication to MCI and mild AD.”
BackgroundLandmark Alzheimer’s drug approval confounds research community
Mullard, A. (2021) · Nature · doi:10.1038/d41586-021-01546-2 · Cited by 157
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4654 · Cited by 149
Sturchio, A., Dwivedi, A. K., Young, C. B., Malm, T., Marsili, L., Sharma, J. S., Mahajan, A., Hill, E. J., Andaloussi, S. E., Poston, K. L., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.100988 · Cited by 128 · cited 1×
“Secondly, there is no evidence that Aβ reduction correlates with clinical benefits, so the majority of experts consider that Aβ plaques are not a valid surrogate endpoint.(10,60) Moreover, recent studies showed that tau accumulation correlates better with cognitive impairment than Aβ.”
BackgroundPenke, B., Szűcs, M., & Bogár, F. (2020) · Molecules · doi:10.3390/molecules25071659 · Cited by 114
Penninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9722-5 · Cited by 75
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66 · cited 1×
“Thirdly, the close collaboration between the FDA and the sponsor could have impacted the objectivity of the FDA’s decision.(63,64) Furthermore, the AD ́s advocacy groups exerted much pressure on the FDA, defending that a marginal benefit of aducanumab would be significant to patients and caregivers.”
BackgroundAducanumab for Alzheimer’s disease: A regulatory perspective
Nisticò, R., & Borg, J. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105754 · Cited by 60 · cited 2×
“EMA and PMDA Decisions In Europe, aducanumab was under review at the EMA since October 2020 (Figure 1).(14,42) On December 17, 2021, the EMA’s Committee for Medicinal Products for Human Use recommended the rejection of the marketing application for AduhelmTM.”
BackgroundMethodAlzheimer's and Aducanumab: Unjust Profits and False Hopes
Fleck, L. M. (2021) · Hastings Center Report · doi:10.1002/hast.1264 · Cited by 50 · cited 2×
“The FDA should have required a third phase 3 trial with a high-dose of aducanumab before approval.(37,59) Secondly, there is no evidence that Aβ reduction correlates with clinical benefits, so the majority of experts consider that Aβ plaques are not a valid surrogate endpoint.”
BackgroundCost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease
Whittington, M. D., Campbell, J. D., Rind, D., Fluetsch, N., Lin, G. A., & Pearson, S. D. (2022) · Neurology · doi:10.1212/wnl.0000000000013314 · Cited by 50
Three FDA advisory panel members resign over approval of Alzheimer’s drug
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n1503 · Cited by 48 · cited 1×
“Contrary to the independent committee decision, the FDA granted accelerated approval to aducanumab on June 7, 2021, leading to the resignation of three members of the PCNS committee.(20,40) The accelerated approval pathway allows patients to have early access to drugs that target a serious disease and which provide a…”
BackgroundAducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n3127 · Cited by 47
Gyawali, B., Ross, J. S., & Kesselheim, A. S. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.4604 · Cited by 44 · cited 1×
“As a result, some experts are now questioning the utility of FDA ́s accelerated approvals, showing concerns about its increasing frequency, and suggesting reform of this pathway.(77)”
BackgroundRecently Approved Alzheimer Drug Raises Questions That Might Never Be Answered
Rubin, R. (2021) · JAMA · doi:10.1001/jama.2021.11558 · Cited by 42 · cited 10×
“In Europe, aducanumab was under review at the EMA since October 2020 (Figure 1).14,42 On December 17, 2021, the EMA’s Committee for Medicinal Products for Human Use recommended the rejection of the marketing application for Aduhelm™.22,43,44 According to the performed studies, EMA experts considered that this drug did…”
BackgroundInfluentialAducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 40 · cited 1×
“Researchers are concluding that both Aβ and tau protein has a major role in the neurodegeneration process and they interfere with each other.(78) Thus, a combination therapy targeting the accumulation of Aβ aggregates (upstream pathology) and the intracellular tau accumulation (downstream pathology) have the potential…”
BackgroundRegulatory decisions diverge over aducanumab for Alzheimer’s disease
Lythgoe, M. P., Jenei, K., & Prasad, V. (2022) · BMJ · doi:10.1136/bmj-2021-069780 · Cited by 32 · cited 3×
“At the time of press, Biogen is appealing against EMA’s decision.(23,44) Shortly after the EMA’s decision, the Japanese Medicines agency also denied the approval of aducanumab.”
BackgroundMethodInfluentialUnblinded by the light: amyloid‐related imaging abnormalities in Alzheimer’s clinical trials
Gleason, A. J., Ayton, S., & Bush, A. I. (2020) · European Journal of Neurology · doi:10.1111/ene.14484 · Cited by 23
Imbimbo, B. P., Ippati, S., & Watling, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1793755 · Cited by 21
Combination therapy for Alzheimer's disease and related dementias
Bednar, M. M. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.10.001 · Cited by 9 · cited 10×
“In Europe, aducanumab was under review at the EMA since October 2020 (Figure 1).14,42 On December 17, 2021, the EMA’s Committee for Medicinal Products for Human Use recommended the rejection of the marketing application for Aduhelm™.22,43,44 According to the performed studies, EMA experts considered that this drug did…”
BackgroundInfluentialLythgoe, M., & Prasad, V. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.012 · Cited by 8 · cited 2×
“Finally, the authors indicated that the large time given to Biogen to complete the confirmatory trial (9 years) could set a precedent for companies to delay the completion of this trial.(76) As a result, some experts are now questioning the utility of FDA ́s accelerated approvals, showing concerns about its increasing…”
BackgroundFDA Approval of Aducanumab Divided the Community but Also Connected and United It
Hooker, J. M. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00393 · Cited by 7
Castrillo‐Viguera, C., Chalkias, S., Burkett, P., Wu, S., Chen, H., Harrison, K., Yurgalevitch, C., & Haeberlein, S. B. (2021) · Neurology · doi:10.1212/wnl.96.15_supplement.2448 · Cited by 4
Mixed Response to the CMS Decision on Coverage for Aducanumab
Butcher, L. (2022) · Neurology Today · doi:10.1097/01.nt.0000821676.02301.7a · Cited by 3 · cited 1×
“There has been a considerable debate since the announcement that CMS planned to limit AduhelmTM coverage.(72) The CMS decision includes the whole class of anti-Aβ antibodies, which also affect lecanemab, donanemab, and gantenerumab.”
Background
Research works printed but not linked: 6
- World Health Organization. Global action plan on the public health response to dementia 2017–2025. Geneva:World Heal Organ; 2017: 27. Available from: http://www.who.int/mental_health/neurology/dementia/action_plan_2017_2025/en/. Accessed May 14, 2022.
- Eisai. Japan’s first committee on new drugs of the pharmaceutical affairs and food sanitation council seeks additional data; aducanumab remains under review. Eisai Global; 2021. Available from: https://www.eisai.com/news/2021/news2021101.html. Accessed April 9, 2022.
- Bussiere, 2013, Neurodegener Dis, 11, 2576
- Biogen. Update on regulatory review of aducanumab in the European Union. Biogen. Available from: https://investors.biogen.com/news-releases/news-release-details/update-regulatory-submission-aducanumab-european-union.; 2021. Accessed April 9, 2022.
- Institute for Clinical and Economic Review. ICER issues statement on the FDA’s approval of aducanumab for Alzheimer’s disease. ICER; 2021. Available from: https://icer.org/news-insights/press-releases/icer-issues-statement-on-The-fdas-approval-of-aducanumab-for-alzheimers-disease/. Accessed November 11, 2021.
- Association AF. Aduhelm lowers tau; registry to track real-world performance | ALZFORUM. Alzforum; 2021. Available from: https://www.alzforum.org/news/conference-coverage/aduhelm-lowers-tau-registry-track-real-world-performance. Accessed February 1, 2022.
Cited by
Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.047 · Cited by 228
Safiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications
Doran, S. J., & Sawyer, R. P. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1326784 · Cited by 147
“The incidence of ARIA is variable with the different anti-amyloid therapeutics with ARIA-E incidence ranging from 0.9–40.6% (Table 1; Carlson et al., 2016; Avgerinos et al., 2021; Barakos et al., 2022; Jeong et al., 2022; Salloway et al., 2022; Vaz et al., 2022).”
BackgroundInfluentialTang, B., Wang, Y., & Ren, J. (2023) · Ibrain · doi:10.1002/ibra.12098 · Cited by 137
“In December 2021, the European Medicines Agency denied the approval of aducanumab for AD treatment, resulting in more skepticism as to whether the drug is effective and safe.(38) Also, aducanumab is expensive: about $28,000 per person per year, making it unaffordable for the average family.”
BackgroundFišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 120
“The mechanism of action of aducanumab (significant reduction of Aβ in the cerebral cortex) supports the amyloid hypothesis of AD [349]; however, its effect on the progression of cognitive decline or dementia in AD cannot be considered proven [319,350].”
Background
Metadata
- Authors
- Vaz, M., Silva, V., Monteiro, C., & Silvestre, S.
- Affiliations
- University of Beira Interior (PT)
- Corresponding author
- Vaz, Miguel
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2022-05
- Volume
- Volume 17
- Pages
- 797-810
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- PMC
- PMC9124475
- OpenAlex
- W4280613528
- Cited by
- 183
- References
- 48
- Citations by year
- 2026: 26 · 2025: 42 · 2024: 58 · 2023: 41 · 2022: 16
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Interventions in Aging (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Programa Operacional Regional do Centro (CENTRO-01-0145-FEDER-000013)
- Fundação para a Ciência e a Tecnologia (UID/Multi/00709, UID/Multi/00709/2019, 01-0145, COMPETE, POCI-01-0145, POCI-01-0145-FEDER-, COMPETE_2020, 00709/2019, POCI-01-, POCI-01-0145-FEDER- 007491, CENTRO-01-0145-FEDER-000013, 007491, 00709)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, accelerated approval, tau pathology, combination therapy, drug safety, drug costs, regulatory decision-making
- MeSH terms
- Alzheimer Disease, Humans, United States, United States Food and Drug Administration, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

